Capital Fund Management S.A. Fibrogen Inc Transaction History

Capital Fund Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$10.18 - $26.64 $104,599 - $273,726	-10,275 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$18.57 - $35.68 $190,806 - $366,612	10,275 New	10,275 $273,000
Q4 2020 Feb 12, 2021	SELL	$37.09 - $48.97 $415,333 - $548,366	-11,198 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$40.47 - $45.5 $744,324 - $836,836	-18,392 Reduced 62.16%	11,198 $460,000
Q2 2020 Aug 13, 2020	BUY	$32.57 - $42.83 $697,747 - $917,547	21,423 Added 262.31%	29,590 $1.2 Million
Q1 2020 May 13, 2020	BUY	$23.3 - $45.96 $190,291 - $375,355	8,167 New	8,167 $283,000
Q3 2019 Nov 13, 2019	SELL	$36.98 - $48.45 $265,590 - $347,967	-7,182 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$35.13 - $55.53 $252,303 - $398,816	7,182 New	7,182 $324,000
Q3 2018 Nov 14, 2018	SELL	$56.3 - $67.25 $457,719 - $546,742	-8,130 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$44.9 - $64.95 $365,037 - $528,043	8,130 New	8,130 $509,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.